The role of p16 as putative biomarker for cervical neoplasia: A controversial
            issue?

Gonçalves, Jessica E.S.; Andrade, Cecília Vianna de; Russomano, Fábio Bastos; Nuovo, Gerard J.; Amaro-Filho, Sergio M.; Carvalho, Maria O. O.; Nicol, Alcina F.

doi:10.5935/medicalexpress.2017.06.01

Cited by 9 publications

(10 citation statements)

References 24 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this scenario, anti-proliferative p16 gene product seems to elevate for compensation of non-functional state of foremost tumor suppressor pRb and p53 genes [9][10][11]. Thus, over expression of p16 has become the bio marker of choice to identify transcriptionally active, hence high-risk HPV, by immunohistochemical profiles [11][12][13]. Over expression of p16 gene has been associated with HPV related: cervical cancer, oral squamous cell carcinoma, oropharyngeal squamous cell carcinoma, head and neck cancer (HNSCC) well as non-small-cell lung cancer [11][12][13][14][15][16][17].…”

Section: Communicationmentioning

confidence: 99%

Snapshot of Clinical Implications of p16 Overexpression in Carcinogenesis

Perera¹,

Perera²

2021

COR

View full text Add to dashboard Cite

Molecular markers are needed to decide the treatment plans of certain cancer types when the histological and other clinical diagnoses are not sufficient to decide the tumor nodular metastasis (TNM) stage. The ubiquitous p16 gene is one of them gained popularity by fulfilling criteria to be a useful biomarker. Over expression of p16, to compensate the inactivity of another two tumor suppressor genes (TSG)s, pRb and p53 due to the integration of E7 and E6 high risk Human Papilloma viral oncoprotein respectively into the host keratinocytes is useful to consider the clinical impact of p16 biomarker in carcinogenesis. The p16 immunohistochemistry helps the diagnosis as well as prognosis of cervical and oropharyngeal squamous cell carcinoma, though there are ambiguities in the cutoff values of p16 positivity. There is also a re-emerging interest on clinical impact of p16 positivity in lung, breast, and colorectal cancer types. High risk HPV genotypes have been already established as the aetiological agents of cervical, other rare ano-genital and oropharyngeal (especially tonsils and base of the tongue) cancers. The HPV associated subset of head and neck cancers demonstrate a unique tumor biology, when compared with HPV non associated ones thus, most effective treatment planning including counselling is much needed to maximize the overall survival of HPV associated cancer patients, in the era of personalized precision medicine. In the shed of light, this communication glimpses on clinical implications of p16 overexpression in carcinogenesis not limiting to cervical and a subset of head and neck carcinomas (HNSCC).

show abstract

Section: Communicationmentioning

confidence: 99%

Snapshot of Clinical Implications of p16 Overexpression in Carcinogenesis

Perera¹,

Perera²

2021

COR

View full text Add to dashboard Cite

show abstract

“…However, in HPV-positive cells, the pRb is inactivated by E7, thus resulting in the significant overexpression of the p16-encoded protein in HPV-positive cancer cells ( 26 ). Although p16 is a putative biomarker for HPV-transformed cervical neoplasia, it has some drawbacks, such as insufficient standardization and interpretation of the different immunoreactive stain, that make this method controversial ( 27 ). The possibility of HPV proteins as promising diagnostic and therapeutic targets is thus under reconsideration.…”

Section: Introductionmentioning

confidence: 99%

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

Dong

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Infection with human papillomavirus (HPV) is one of the main causes of malignant neoplasms, especially cervical, anogenital, and oropharyngeal cancers. Although we have developed preventive vaccines that can protect from HPV infection, there are still many new cases of HPV-related cancers worldwide. Early diagnosis and therapy are therefore important for the treatment of these diseases. As HPVs are the major contributors to these cancers, it is reasonable to develop reagents, kits, or devices to detect and eliminate HPVs for early diagnosis and therapeutics. Immunological methods are precise strategies that are promising for the accurate detection and blockade of HPVs. During the last decades, the mechanism of how HPVs induce neoplasms has been extensively elucidated, and several oncogenic HPV early proteins, including E5, E6, and E7, have been shown to be positively related to the oncogenesis and malignancy of HPV-induced cancers. These oncoproteins are promising biomarkers for diagnosis and as targets for the therapeutics of HPV-related cancers. Importantly, many specific monoclonal antibodies (mAbs), or newly designed antibody mimics, as well as new immunological kits, devices, and reagents have been developed for both the immunodiagnosis and immunotherapeutics of HPV-induced cancers. In the current review, we summarize the research progress in the immunodiagnosis and immunotherapeutics based on HPV for HPV-induced cancers. In particular, we depict the most promising serological methods for the detection of HPV infection and several therapeutical immunotherapeutics based on HPV, using immunological tools, including native mAbs, radio-labelled mAbs, affitoxins (affibody-linked toxins), intracellular single-chain antibodies (scFvs), nanobodies, therapeutical vaccines, and T-cell-based therapies. Our review aims to provide new clues for researchers to develop novel strategies and methods for the diagnosis and treatment of HPV-induced tumors.

show abstract

“…Cervical cancer is the second common cancer in underdeveloped countries among females 1 . The Human Papilloma Virus (HPV) is a proven etiological factor 1,3,4 . The age range for cervical cancer is reported to be 27-80 years with mean age of 54.2 years; the maximum cases have been noted between 41-60 years of age 1 .…”

Section: Introductionmentioning

confidence: 99%

“…Use of P16 as an adjuvant biomarker has improved diagnostic agreement 6 . P16 expression indicates infection with high risk HPV (HR-HPV) and integration of viral genome with host genome 4 . Different pathologists use different criteria and threshold for interpretation of P16 expression 7,8 .…”

Section: Introductionmentioning

confidence: 99%

Expression of P16 biomarker in squamous cell carcinoma of uterine cervix and its association with clinico-pathological parameters: A cross-sectional study

2020

View full text Add to dashboard Cite

Introduction: Cervical cancer is the most common cancer among females. P16 is the surrogate marker for cervical carcinoma. This study aimed to evaluate the association of P16 marker with clinic-pathological parameters in squamous cell carcinoma of uterine cervix. Methods: This was a cross-sectional study. Histological confirmed cases of squamous cell carcinoma (SCC) of cervix were considered. All cases were evaluated for IHC P16 expression as per lower anogenital squamous terminology (LAST) criteria and correlated with clinico-pathological parameters. The data was analyzed by SPSS software version 22. Results: Out of 75 cases, P16 biomarker expression was block positive, ambiguous and negative in 67 (89.3%), 5 (6.6%), and 3 (4%) cases, respectively. There was a significant association between P16 expression and age (p = 0.005). All cases between 30-59 years of age showed block positivity. There was no significant association between P16 expression and age at marriage (p = 0.951), age at menopause (p = 0.311), parity (p = 0.554), clinical symptoms/signs, stage of disease (p = 0.28), or histopathological grade (p = 0.877). Maximum expression was seen between 40-44 years. Moreover, all cases having 1 & 2 parity showed block positivity and all stage I cases showed block positivity. Conclusion: P16 biomarker was significantly expressed in cervical cancers of the relatively younger age group and those with early stage of disease.

show abstract

The role of p16 as putative biomarker for cervical neoplasia: A controversial issue?

Cited by 9 publications

References 24 publications

Snapshot of Clinical Implications of p16 Overexpression in Carcinogenesis

Snapshot of Clinical Implications of p16 Overexpression in Carcinogenesis

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

Expression of P16 biomarker in squamous cell carcinoma of uterine cervix and its association with clinico-pathological parameters: A cross-sectional study

Contact Info

Product

Resources

About